59147-02-3

Basic information

• Product Name: 4-(2-FURYL)ANILINE
• Synonyms: 4-(2-FURYL)ANILINE;4-(2-FURYL)ANILINE HYDROCHLORIDE;4-FURAN-2-YL-PHENYLAMINE;AKOS BAR-0084;CHEMBRDG-BB 4003073;4-Fur-2-ylaniline hydrochloride;4-(2-Furyl)aniline 97%;[4-(2-furyl)phenyl]amine hydrochloride
• CAS NO: 59147-02-3
• Molecular Formula: C₁₀H₉NO
• Molecular Weight: 159.18
• Mol File: 59147-02-3.mol
• Article Data: 11

Chemical Properties

• Melting Point: 55.5-57
• Boiling Point: 276.8 °C at 760 mmHg
• Flash Point: 121.2 °C
• Appearance: /
• Density: 1.138 g/cm³
• Vapor Pressure: 0.00469mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.99±0.10(Predicted)
• CAS DataBase Reference: 4-(2-FURYL)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-FURYL)ANILINE(59147-02-3)
• EPA Substance Registry System: 4-(2-FURYL)ANILINE(59147-02-3)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 59147-02-3(Hazardous Substances Data)

Usage

General Description

4-(2-FURYL)ANILINE, also known as furylaniline or 2-furylaniline, is a chemical compound with the molecular formula C10H10N2O. It is an aniline derivative with a furan ring and an amino group attached to the benzene ring. This chemical is used in the production of dyes, pharmaceuticals, and agricultural chemicals. It is also used in the manufacturing of rubber and other materials as a cross-linking agent. Additionally, 4-(2-furyl)aniline has potential applications in medicinal and bioorganic chemistry due to its unique structure and functional groups. However, it is important to handle this chemical with caution as it may be harmful if ingested or inhaled and can cause skin and eye irritation.

InChI:InChI=1/C10H9NO/c11-9-5-3-8(4-6-9)10-2-1-7-12-10/h1-7H,11H2

Upstream product

• 28123-72-0 2-(4-nitrophenyl)furan 
• 100-01-6 4-nitro-aniline 
• 17763-80-3 para-nitrophenyl triflate 
• 540-37-4 p-aminoiodobenzene 
• 13331-23-2 fur-2-ylboronic acid 
• 106-40-1 4-bromo-aniline 
• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 586-78-7 para-nitrophenyl bromide 

Downstream Products

• 69836-64-2 N-(4-furan-2-ylphenyl)acetamide 
• 102269-43-2 Diethyl ester of N<4-(furyl-2)phenyl>aminomethylenemalonic acid 
• 868755-79-7 2-(4-(furan-2-yl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1609111-40-1 2-azido-4-(furan-2-yl)aniline 
• 1257651-75-4 N-(4-(furan-2-yl)phenyl)-2-(1H-indol-3-yl)-2-oxoacetamide 
• 100191-85-3 2-(4'-N,N-dimethylaminophenyl)furan 

Relevant articles and documents

[9,9]-Sigmatropic Shift in a Benzidine-Type Rearrangement

-

Novel substituted benzoyl compound and its pharmaceutically acceptable salt and preparation method and application (by machine translation)

The invention relates to the general formula I shown novel substituted benzoyl compound and its pharmaceutically acceptable salt and preparation method and application. The invention also provides pharmaceutical compositions containing them, in vitro and in vivo anti-tumor effect results and acute toxicity study, the obtained anti-tumor drug model substituted benzoyl compound, has more excellent anti-tumor activity and safety, can be in the treatment of leukemia, lung cancer, colon cancer, ovarian cancer and renal carcinoma tumor in the application, so that the therapeutic window, so in the medical field as antitumor agents in the very application value. (by machine translation)

Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)

The X-ray structure of the previously reported PPARδ modulator 1 bound to the ligand binding domain (LBD) revealed that the amide moiety in 1 exists in the thermodynamically disfavored cis-amide orientation. Isosteric replacement of the cis-amide with five-membered heterocycles led to the identification of imidazole 17 (MA-0204), a potent, selective PPARδ modulator with good pharmacokinetic properties. MA-0204 was tested in vivo in mice and in vitro in patient-derived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); 17 altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.